The use of multifunctional polymers for non-invasive peptide and protein application

Bibliography

• PILLAI O, NAIR V, PODURI R, PANCHAGNULA R: Transdermal iontophoresis. Part II: peptide and protein delivery. Methods Find. Exp. Clin. Pharmacol (1999) 21:229–240.
   Google Scholar
• SRINIVASAN V, HIGUCHI WI, SIMS SM, GHANEM AH, BEHL CR: Transdermal iontophoretic drug delivery: mechanistic analysis and application to polypeptide delivery. J. Pharm. Sci. (1989) 78:370–375.
   PubMed Web of Science ®Google Scholar
• BERNKOP-SCHNURCH A: Strategien zur peroralen Applikation von Peptid- und Proteinwirkstoffen. Sci. Pharm. (1997) 65:61–81.
   Google Scholar
• KOLAC C, STREICHHAN P, LEHR CM: Oral bio availability of proteolytic enzymes. Eur.J. Pharm. Biopharm. (1996) 42:222–232.
   Web of Science ®Google Scholar
• MATTHEWS DM: Peptide absorption. Gastroenterology(1976) 71:151–161.
   PubMed Web of Science ®Google Scholar
• CLAUSEN A, BERNKOP-SCHNORCH A: In vitro evalua-tion of the permeation enhancing effect of thiolated polycarbophil. j Pharm. Sci. (2000) [In Press].
   Google Scholar
• WILSON CG, WASHINGTON N: Physiological Pharmaceu-tics. Ellis Harwood Ltd. Publisher, Chichester, UK (1989).
   Google Scholar
• STEFFENS K-J: Persorption -criticism and agreement as based upon in vitro and in vivo studies on mammals. In: Absorption of orally administered enzymes. Gardner MLG, Steffens K-J (Eds.), Springer-Verlag, Berlin, Germany (1995).
   Google Scholar
• HEYMAN M, CRAIN-DENOYELLE AM, NATH SK, DESJEUXJF: Quantification of protein transcytosis in the human colon carcinoma cell line CaCo-2. J Cell Physiol. (1990) 143:391–395.
   PubMed Web of Science ®Google Scholar
• CAMPBELL BJ: Biochemical and functional aspects of mucus and mucin-type glycoproteins. In: Bioadhesive Drug Delivery Systems. Mathiowitz E, Chickering DE III, Lehr C-M (Eds.), Marcel Dekker, New York, USA (1999):85.
   Google Scholar
• BERNKOP-SCHNORCH A, FRAGNER R: Investigations into the diffusion behaviour of polypep tides in native intestinal mucus with regard to their peroral admini-stration. Pharm. Sci. (1996) 2:361–363.
   Google Scholar
• BERNKOP-SCHNORCH A: The use of inhibitory agents to overcome the enzymatic barrier to perorally adminis-tered therapeutic peptides and proteins. j Control. Release (1998) 52:1–16.
   PubMedGoogle Scholar
• •A useful review of the enzymatic barrier and the use of enzyme inhibitors.
   Google Scholar
• IKESUE K, KOPECKOVA P, KOPECEK J: Degradation of proteins by guinea pig intestinal enzymes. Int. J Pharm. (1993) 95:171–179.
   Web of Science ®Google Scholar
• LUEBEN HL, BOHNER V, PERARD D et al.: Mucoadhesive polymers in peroral peptide drug delivery. V. Effect of poly(acrylates) on the enzymatic degradation of peptide drugs by intestinal brush border membrane vesicles. Int. J Pharm. (1996) 141:39–52.
   Google Scholar
• DAMAGE C, MICHEL C, APRAHAMIAN M, COUVREUR P: New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes (1988) 37:246–251.
   PubMed Web of Science ®Google Scholar
• CARINO GP, JACOB JS, MATHIOWITZ E: Nanosphere based oral insulin delivery. j Control. Release (2000) 65:261–269.
   PubMed Web of Science ®Google Scholar
• KAWASHIMA Y, YAMAMOTO H, TAKEUCHI H, KUNO Y:Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol (2000) 5:77–85.
   PubMed Web of Science ®Google Scholar
• SHAO PG, BAILEY LC: Porcine insulin biodegradablepolyester microspheres: stability and in vitro release characteristics. Pharm. Dev. Technol. (2000) 5:1–9.
   PubMed Web of Science ®Google Scholar
• MOLPECERES J, CHACON M, GUZMAN M, BERGES L, DELROSARIO ABERTURAS M: A polycaprolactone nanop ar-ticle formulation of cyclosporin-A improves the of area under the curve using a limited sampling strategy. Int. j Pharm. (1999) 187:101–113.
   PubMed Web of Science ®Google Scholar
• BRUNNER A, MADER K, GOPFERICH A: pH and osmoticpressure inside biodegradable microspheres during erosion. Pharm. Res. (1999) 16:847–853.
   PubMed Web of Science ®Google Scholar
• JANI P, HALBERT GW, LANGRIDGE J, FLORENCE AT: Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm. Pharmacol (1990) 42:821–826.
   PubMed Web of Science ®Google Scholar
• •This study gives a good explanation of the potential of nanoparticles for the non-invasive application of peptide drugs.
   Google Scholar
• FLORENCE AT: The oral absorption of micro- and nanoparticles: neither exceptional nor unusual. Pharm. Res. (1997) 14:259–266.
   PubMed Web of Science ®Google Scholar
• EBEL JP: A method for quantifying particle absorption from the small intestine of the mouse. Pharm. Res. (1990) 7:848–851.
   PubMed Web of Science ®Google Scholar
• THOMAS NW, JENKINS PG, HOWARD KA et al.: Particleuptake and tr an slo cation across epithelial membranes. J Anat. (1996) 189:487–490.
   PubMedGoogle Scholar
• MORISHITA M, MORISHITA I, TAKAYAMA K, MACHIDA Y, T: Novel oral microspheres of insulin with protease inhibitor protecting from enzymatic degradation. Int. J. Pharm. (1992) 78:1–7.
   Web of Science ®Google Scholar
• •Shows the necessity of protecting peptide drugs from enzymatic degradation.
   Google Scholar
• CRITCHLEY H, DAVIS SS, FARRAJ NF, ILLUM L: Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. J. Pharm. Pharmacol (1994) 46:651–656.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI H, YAMAMOTO H, TOSHIYUKI N, TOMOAKIH, KAWASHIMA Y: Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. (1996) 13:896–901.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI H, MATSUI Y, YAMAMOTO H, KAWASHIMA Y: liposomes coated with chitosan or carbopol for oral administration of peptide drugs. Proc. Int. Symp. Control. Release Bioactive Mater. (1999) 26:6372.
   Google Scholar
• ••Shows the potential of multifunctional polymers for oraladministration of peptide drugs.
   Google Scholar
• BERNKOP-SCHNORCH A, SCHVVARZ V, STEININGER S: Polymers with thiol groups: a new generation of mucoadhesive polymers? Pharm. Res. (1999) 16:876–881.
   Google Scholar
• MARSCHOTZ M, CALICETI P, BERNKOP-SCHNORCH A: Design and in vivo evaluation of an oral delivery system for insulin. Pharm. Res. (2000) [In Press].
   Google Scholar
• ••Provides evidence for the use of polymer-inhibitorconjugates as a promising strategy to improve the bioavail-ability of orally given peptide drugs.
   Google Scholar
• BERNKOP-SCHNORCH A, HUMENBERGER C, VALENTA C: studies on bioadhesive delivery systems for peptide and protein drugs. InL J. Pharm. (1998) 165:217–225.
   Google Scholar
• LUEBEN HL, RENTEL C-0, KOTZE AF et al.: Mucoadhesive polymers in peroral peptide drug delivery. W. Polycar-bophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. .1 Control. Release (1997) 45:15–23.
   Google Scholar
• LUEBEN HL, DE LEEUW BJ, LANGEMEYER MW, DE BOER AG, VERHOEF JC, JUNGINGER HE: Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorp-tion of the peptide drug buserelin in viva Pharm. Res. (1996) 13:1668–1672.
   Google Scholar
• ILLUM L, FARRAJ NF, DAVIS SS: Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. (1994) 11:1186–1189.
   PubMed Web of Science ®Google Scholar
• ••Identifies the potential use of chitosan as a multifunctionalpolymer for the nasal delivery of peptide drugs.
   Google Scholar
• LUEBEN HL, VERHOEF JC, BORCHARD G, LEHR C-M, DE AG, JUNGINGER HE: Mucoadhesive polymers in the peroral peptide drug delivery: II. carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm. Res. (1995) 12:1293–1298.
   Google Scholar
• BERNKOP-SCHNeRCH A, PAIKL CH, VALENTA C: Novel bioadhesive chitosan-EDTA conjugate protects leucine enkephalin from degradation by aminopeptidase N.. Res. (1997) 14:917–922.
   Google Scholar
• BERNKOP-SCHNeRCH A, KRAJICEK ME: Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: synthesis and evaluation of different chitosan-EDTA conjugates. j Control. Release (1998) 50:215–223.
   PubMedGoogle Scholar
• FUJII S, YOKOYAMA T, IKEGAYA K, SATO F, YOKOO N: Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J. Pharm. Pharmacol (1985) 37:545–549.
   PubMed Web of Science ®Google Scholar
• LANGGUTH P, MERKLE HP, AMIDON GL: Oral absorp-tion of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. Pharm. Res. (1994) 11:528–535.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO A, TANIGUCHI T, RIKYUU K et al.: Effects of various protease inhibitors on the intestinal absorp-tion and degradation of insulin in rats. Pharm. Res. (1994) 11:1496–1500.
   PubMed Web of Science ®Google Scholar
• BERNKOP-SCHNeRCH A: Polymer-inhibitor conjugates: a promising strategy to overcome the enzymatic barrier to perorally administered (poly)peptide drugs? STP Pharma Sciences (1999) 9:78–87.
   Google Scholar
• BERNKOP-SCHNeRCH A, MARSCHÜTZ M: Developmentand in vitro evaluation of systems to protect peptide drugs from aminopeptidase N. Pharm. Res. (1997) 14:181–185.
   PubMedGoogle Scholar
• BERNKOP-SCHNeRCH A, APPRICH I: Synthesis andevaluation of a modified mucoadhesive polymer protecting from a-chymotrypsinic degradation. Int. J Pharm. (1997) 146:247–254.
   Google Scholar
• BERNKOP-SCHNeRCH A, GOCKEL NC: Development and analysis of a polymer protecting from luminal degradation caused by a-chymotrypsin. Dev. Ind. Pharm. (1997) 23:733–740.
   Google Scholar
• BERNKOP-SCHNeRCH A, SCHWARZ GH, KRATZEL M: Modified mucoadhesive polymers for the peroral administration of mainly elastase degradable therapeutic (poly)peptides. j Control. Release (1997) 47:113–121.
   Google Scholar
• WILDING IR, DAVIS SS, POZZI F, FURLANI P, GAZZANIGAA: Enteric coating timed release system for colonic targeting. Int. J. Pharm. (1994) 11:99–102.
   Google Scholar